Q-linea receives first ASTar orders under new commercialization strategy
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received the first two orders for ASTar instruments from Pro-Lab Diagnostics in the UK. The instruments will be utilized at upcoming exhibitions and in future customer evaluations.
“Having completed successful training for our technical sales, application support and engineering teams, we are all very much dedicated to the full launch of the Q-linea range across the UK. The commitment of all parties involved is at the highest level. A series of interactive seminars will be starting at various “exciting” locations across the UK very soon”, said Mark Reed, General manager of Pro-Lab Diagnostics.
“After a very successful training week with the Pro-Lab team at our site in Uppsala, it is impressive to see the high intensity in market activities in the UK. We are looking forward to a great collaboration,” said Thomas Fritz, Chief Commercial Officer of Q-linea.
“Pro-Lab is a very strong distribution partner and an important pillar for our revised commercial strategy. With these orders their strong commitment to ASTar and rapid AST testing has been truly confirmed”, said Jonas Jarvius, CEO of Q-linea.
About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.